Fundsmith LLP boosted its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 2.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,553,141 shares of the medical instruments supplier’s stock after buying an additional 52,272 shares during the period. C.R. Bard comprises about 7.4% of Fundsmith LLP’s holdings, making the stock its 4th largest position. Fundsmith LLP owned approximately 3.54% of C.R. Bard worth $633,996,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Haverford Trust Co. boosted its stake in C.R. Bard by 0.3% in the fourth quarter. Haverford Trust Co. now owns 4,012 shares of the medical instruments supplier’s stock worth $901,000 after buying an additional 11 shares in the last quarter. Keybank National Association OH boosted its stake in C.R. Bard by 0.3% in the fourth quarter. Keybank National Association OH now owns 4,353 shares of the medical instruments supplier’s stock worth $978,000 after buying an additional 13 shares in the last quarter. ETRADE Capital Management LLC boosted its stake in C.R. Bard by 1.7% in the third quarter. ETRADE Capital Management LLC now owns 1,054 shares of the medical instruments supplier’s stock worth $236,000 after buying an additional 18 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in C.R. Bard by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,215 shares of the medical instruments supplier’s stock worth $947,000 after buying an additional 20 shares in the last quarter. Finally, Burns J W & Co. Inc. NY boosted its stake in C.R. Bard by 1.3% in the first quarter. Burns J W & Co. Inc. NY now owns 1,581 shares of the medical instruments supplier’s stock worth $393,000 after buying an additional 21 shares in the last quarter. 88.32% of the stock is owned by institutional investors.
Shares of C.R. Bard, Inc. (NYSE BCR) opened at 313.56 on Friday. The stock has a market capitalization of $22.71 billion, a P/E ratio of 39.91 and a beta of 0.64. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $315.29. The company’s 50-day moving average is $309.48 and its 200 day moving average is $257.26.
C.R. Bard (NYSE:BCR) last issued its earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.22. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The business had revenue of $938.80 million during the quarter, compared to analyst estimates of $916.15 million. During the same period in the prior year, the company posted $2.34 earnings per share. C.R. Bard’s revenue was up 7.5% on a year-over-year basis. On average, equities analysts forecast that C.R. Bard, Inc. will post $11.78 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Shareholders of record on Monday, July 24th will be paid a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 annualized dividend and a yield of 0.33%. C.R. Bard’s dividend payout ratio is currently 13.21%.
WARNING: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/06/18/fundsmith-llp-has-633-996-million-stake-in-c-r-bard-inc-bcr-updated-updated.html.
A number of research firms recently weighed in on BCR. BMO Capital Markets restated a “buy” rating and set a $255.00 price target on shares of C.R. Bard in a research report on Tuesday, April 11th. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $276.00 price target on the stock in a research report on Friday, March 3rd. Morgan Stanley lowered shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research report on Monday, April 24th. Finally, Jefferies Group LLC boosted their target price on shares of C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a report on Monday, April 24th. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. C.R. Bard has a consensus rating of “Hold” and a consensus target price of $265.62.
In other C.R. Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the stock in a transaction on Monday, April 24th. The stock was sold at an average price of $304.00, for a total transaction of $1,101,088.00. Following the completion of the transaction, the vice president now directly owns 10,139 shares in the company, valued at $3,082,256. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.80% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.